Latest RVMD news and sentiment

Revolution Medicines Got Its Breakthrough—What Moves It Next?

Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Revolution Medicines, Inc. (RVMD). Shares have added about 6.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Revolution Medicines due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Loss Wider Than Expected, Sales Nil Revolution Medicines reported an adjusted loss of $2.34 per share in the sec

Patients with the deadliest cancer finally have something that works

For decades, a pancreatic cancer diagnosis came with almost no good options. The disease is usually caught late, spreads fast, and resists most treatments. Patients and their families were often left with months, not years. That grim picture just changed. On Aug. 26, the U.S. Food and Drug Administrationapproved Rasonque daraxonrasib, a once-daily pill from Revolution Medicines (RVMD). It is the first broad RAS-targeted medicine cleared for adults with metastatic pancreatic cancer who have already had chemotherapy. For investors, the approval turns a research-stage company into one with a prod

Revolution Medicines (RVMD) After RASONQUE Approval Is The Valuation Story Still Intact

Revolution Medicines (RVMD) is in focus after the U.S. Food and Drug Administration approved RASONQUE, a once daily oral RAS inhibitor for certain adults with metastatic pancreatic adenocarcinoma following prior treatment. Revolution Medicines' share price has reacted strongly around these developments, with a 1-month share price return of 22.24% and a 3-month share price return of 40.43% helping lift the stock to US$221.15. The 1-year total shareholder return is also very large, indicating powerful positive momentum over both shorter and longer periods. Scan the market for other oncology stoc

RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer

Revolution Medicines RVMD announced that the FDA has approved its RAS inhibitor daraxonrasib for previously treated patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The drug will be marketed under the brand name Rasonque. Why the Approval Is a Big Deal for RVMD The approval marks a major inflection point for Revolution Medicines, making Rasonque the company's first marketed product and transforming it from a clinical-stage biotech into a commercial-stage oncology company. The FDA's decision is supported by data from the phase III RASolute 302 study, which met all its primary a

F.D.A. Approves Drug Poised to Transform Care for Pancreatic Cancer

The FDA has approved a new drug, daraxonrasib, made by Revolution Medicines, for advanced pancreatic cancer. The drug, sold as Rasonque, is taken as two pills a day and has shown significant improvement in life expectancy, doubling it in clinical trials for patients with metastatic pancreatic cancer who have already undergone chemotherapy. While not a cure, it marks a substantial advancement in treating a historically challenging disease, with a monthly sticker price of $39,800, largely expected to be covered by insurance.

What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders

Revolution Medicines(RVMD.US) Officer Sells US$17.99 Million in Common Stock

An officer at Revolution Medicines (RVMD.US) has sold common stock totaling US$17.99 million. This transaction indicates a significant insider sale at the company.

Revolution Medicines (RVMD) CEO trades stock under preset 10b5-1 plan

Revolution Medicines (RVMD) CEO Mark A. Goldsmith exercised options for 80,000 shares and subsequently sold 86,000 shares of common stock, including through revocable trusts, under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2026. The sales occurred at weighted average prices between $206.78 and $212.74, while the options were exercised at $4.73 per share. Goldsmith's reported holdings still include 182,938 restricted stock units.

Revolution Medicines (RVMD) GC trades 56K shares via 10b5-1 plan

Revolution Medicines' General Counsel, Jeff Cislini, exercised stock options for 56,280 shares and subsequently sold 56,894 shares of common stock on August 21, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved sales at weighted average prices ranging from approximately $206.76 to $212.74 per share. Cislini still holds 43,514 restricted stock units after these transactions.

Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze

Quick Read Moderna and Merck's cancer vaccine cut melanoma recurrence risk 49%, sending MRNA up 177% on readout day and 392% year to date. Revolution Medicines' daraxonrasib nearly doubled pancreatic cancer survival versus chemo, with RVMD surging 163% year to date on a $45 billion market cap. AbbVie announced a $10.9 billion Apogee deal and still pledged more M&A capacity as Humira sales collapsed 36% to $756 million. Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Merck didn't make the cut. Grab the names FREE today. Barclays' Emily Field, Head of U.S. Bi

ETFs Investing in Revolution Medicines, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Revolution Medicines, Inc. For each ETF, it provides details such as market value, weight of Revolution Medicines, Inc. stock, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of market segments including total market, small-cap, mid-cap, large-cap, health care, and biotechnology.